Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Clinical trial NCT04055792 · COMPLETED
Trial details
- NCT number
- NCT04055792
- Sponsor
- Henan Cancer Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-11
- Primary completion
- 2023-05-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.